Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19

NCT04400838 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT04400838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04400838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19
Lead sponsor
University of Oxford
Phase
Phase 2/3
Overall status
Completed
Start date
May 28, 2020
Completion date
February 5, 2025
Enrollment
10,811 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus